{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:12Z","timestamp":1787841312292,"version":"build-2784847793"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T00:00:00Z","timestamp":1553212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Janssen and Incyte Corp"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Lymphomatous involvement of the ocular adnexal region (OAR) is generally rare; however, it constitutes the most common ocular malignancy. Most cases of ocular adnexal lymphomas are extra nodal marginal zone B cell lymphomas. Mantle cell lymphoma involvement (MCL) of the OAR is a less common presentation compared with other lymphomas and it has been reported anecdotally. Studies have suggested an association of OAR involvement with poor prognosis. Here, we report the case of a 61 year old man who started experiencing conjunctival erythema which was followed by development of bilateral proptosis. The diagnosis of Stage IV Mantle cell lymphoma with OAR involvement was confirmed 5 months after patient onset of symptomatology. He underwent treatment with systemic chemotherapy, which was followed by high-dose chemotherapy and autologous hematopoietic cell transplant. He is currently day +100 from his transplant and is in complete remission. A review of the literature regarding ocular involvement of MCL is also summarized.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2019.03.002","type":"journal-article","created":{"date-parts":[[2019,4,6]],"date-time":"2019-04-06T10:42:12Z","timestamp":1554547332000},"page":"147-152","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Intraocular involvement of Mantle cell lymphoma"],"prefix":"10.4103","volume":"14","author":[{"given":"Madiha","family":"Iqbal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yennifer Gil","family":"Castano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taimur","family":"Sher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20241211","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1097-0142(197201)29:1<252::AID-CNCR2820290138>3.0.CO;2-#","article-title":"Occurrence and prognosis of extranodal lymphomas","volume":"29","author":"Freeman","year":"1972","journal-title":"Cancer"},{"key":"R2-10-20241211","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1002\/1097-0142(19940501)73:9<2395::AID-CNCR2820730924>3.0.CO;2-V","article-title":"Orbital and adnexal involvement in systemic non-Hodgkin\u2019s lymphoma","volume":"73","author":"Bairey","year":"1994","journal-title":"Cancer"},{"key":"R3-10-20241211","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/01.pas.0000213350.49767.46","article-title":"Lymphoma of the ocular adnexa: A study of 353 cases","volume":"31","author":"Ferry","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R4-10-20241211","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s00417-003-0831-5","article-title":"Prognostic value of cell-cycle markers in ocular adnexal lymphoma: an assessment of 230 cases","volume":"242","author":"Coupland","year":"2004","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R5-10-20241211","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1001\/jamaophthalmol.2017.4810","article-title":"Clinicopathological features of ocular adnexal mantle-cell lymphoma in an international multicenter cohort","volume":"135","author":"Knudsen","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"R6-10-20241211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/aos.12189","article-title":"Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features","volume":"91","author":"Rasmussen","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"R7-10-20241211","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1200\/EDBK_175448","article-title":"Current approaches to Mantle cell lymphoma: diagnosis, prognosis, and therapies","volume":"37","author":"Cohen","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R8-10-20241211","first-page":"83","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview","volume":"102","author":"Sabattini","year":"2010","journal-title":"Pathologica"},{"key":"R9-10-20241211","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z","article-title":"Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors","volume":"82","author":"Bosch","year":"1998","journal-title":"Cancer"},{"key":"R10-10-20241211","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1200\/JCO.2013.52.2466","article-title":"Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network","volume":"32","author":"Hoster","year":"2014","journal-title":"J Clin Oncol"},{"key":"R12-10-20241211","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/bjo.85.1.63","article-title":"Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification. Revised European and American Lymphoma","volume":"85","author":"Auw-Haedrich","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"R13-10-20241211","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1136\/bjo.2008.146910","article-title":"Mantle cell lymphoma in the orbital and adnexal region","volume":"93","author":"Rasmussen","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R14-10-20241211","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1182\/blood-2007-05-075176","article-title":"Lymphoma dissemination: the other face of lymphocyte homing","volume":"110","author":"Pals","year":"2007","journal-title":"Blood"},{"key":"R15-10-20241211","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"R16-10-20241211","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"key":"R18-10-20241211","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387619300275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387619300275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2019.03.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:49:12Z","timestamp":1787838552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2019.03.002"}},"subtitle":["A case report and literature review"],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2019.03.002","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}